ANAPC16

Across TCGA pan-cancer cohorts, ANAPC16 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ANAPC16 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher ANAPC16 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ANAPC16 expression acts as an unfavorable survival marker.

BLCA and LUAD are the cancer types where ANAPC16 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	All	0.153	0.615	.024	6	view →
LUAD	DFS	Median	All	0.213	0.676	.012	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

ANAPC16–BLCA (DFS)

Open the BLCA breakdown →